Please use this identifier to cite or link to this item: https://hdl.handle.net/10923/17876
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWERUTSKY, GUSTAVO-
dc.contributor.authorMALUF, FERNANDO COTAIT-
dc.contributor.authorCRONEMBERGER, EDUARDO HENRIQUE-
dc.contributor.authorCARRERA SOUZA, VINICIUS-
dc.contributor.authorDOS SANTOS MARTINS, SUELEN PATRICIA-
dc.contributor.authorPEIXOTO, FÁBIO-
dc.contributor.authorSMALETZ, OREN-
dc.contributor.authorSCHUTZ, FÁBIO-
dc.contributor.authorHERCHENHORN, DANIEL-
dc.contributor.authorSANTOS, TELMA-
dc.contributor.authorMAVIGNIER CARCANO, FLAVIO-
dc.contributor.authorQUEIROZ MUNIZ, DAVID-
dc.contributor.authorNUNES FILHO, PAULO R. S.-
dc.contributor.authorZAFFARONI, FACUNDO-
dc.contributor.authorBARRIOS, CARLOS-
dc.contributor.authorAndré Poisl Fay-
dc.date.accessioned2021-08-18T18:58:45Z-
dc.date.available2021-08-18T18:58:45Z-
dc.date.issued2019-
dc.identifier.issn1471-2407-
dc.identifier.urihttps://hdl.handle.net/10923/17876-
dc.language.isoen-
dc.relation.ispartofBMC CANCER-
dc.rightsopenAccess-
dc.titleThe LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels-
dc.typeArticle-
dc.date.updated2021-08-18T18:58:43Z-
dc.identifier.doiDOI:10.1186/s12885-019-5709-y-
dc.jtitleBMC CANCER-
dc.volume19-
dc.issue1-
dc.spage487-
Appears in Collections:Artigo de Periódico



All Items in PUCRS Repository are protected by copyright, with all rights reserved, and are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Read more.